We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

A live webcast of the fireside chat will be available on the "Events & Present ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – ...

EST Cathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics (CRSP) todayStay Ahead of the Market:Discover outperforming ...

Check Out Our Latest Stock Report on CRSP Insider Activity at CRISPR Therapeutics In other news, CEO Samarth Kulkarni sold 15,000 shares of the stock in a transaction on Monday, December 2nd. The ...

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock. This data can help you ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target lowered by Bank of America from $98.00 to $85.00 in ...